Buys
Open market- Shares
- Avg price
- Total value
Cameron Turtle - Chief Executive Officer, Director at Spyre Therapeutics, Inc.
Issuer-level insider activity
- Role
- Chief Executive Officer, Director
- Issuer ticker
- SYRE on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Cameron Turtle in Spyre Therapeutics, Inc.
Sells
Open market- Shares
- -150,000
- Avg price
- $39.58
- Total value
- -$5,937,084
Net
Past year- Shares
- -150,000
- Share %
- -100%
- Total value
- -$5,937,084
Reported holdings for Cameron Turtle in Spyre Therapeutics, Inc.
Form 4 holding
Chief Executive Officer, Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 597,540
- Estimated value
- $42,652,405
- Report date
- 01 Jun 2026
- Price
- $71.38
- Ownership
- Direct
Form 4 holding
Chief Executive Officer, Director
Spyre Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 528,000
- Estimated value
- Report date
- 09 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Cameron Turtle in Spyre Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.